COMPUMED, INC. PARTICIPATES IN 7TH EUROPEAN CONGRESS ON CLINICAL AND ECONOMIC ASPECTS OF OSTEOPOROSIS AND OSTEOARTHRITIS COMPANY'S ARTHRITIS APPLICATION FEATURED IN POSTER PRESENTATION
LOS ANGELES, Apr 03, 2007. CompuMed, Inc. (CMPD.OB) -- a medical informatics company leading the development of advanced imaging technology for cost-effective analysis and monitoring -- presented clinical data on its arthritis application at the 7th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO), held March 28-31 in Porto, Portugal.
With about 4,000 attendees, the annual ECCEO meeting is the largest gathering of its kind in Europe for professionals in the fields of osteoporosis and osteoarthritis. The meeting features the latest advancements in epidemiology, pathogenesis, prevention, and treatment. It includes plenary lectures, oral communications and poster sessions drawn from more than 500 abstracts submitted. The goal is to contribute to the effort to make osteoporosis and osteoarthritis diseases of the past.
"We were pleased to be selected to participate at such a prestigious meeting," said CompuMed CEO Jerry McLaughlin. "Our recent $2 million private placement will provide us with the resources to accelerate development of new CAD applications, such as arthritis diagnosis and monitoring."
CompuMed's poster presentation was entitled, "Automatic Computerized Phalangeal Joint Space Width Measurement in Females." The objective of the Company's study was to perform automatic computerized measurement of phalangeal joint space width, and compare the results to manual measurements in 100 female subjects. Quantitative assessment of joint space width aids the diagnosis and monitoring of both osteoarthritis and inflammatory arthritis. There are currently no cost-effective methods to evaluate these disease criteria. Consequently, clinicians have to rely on patient symptoms or tedious, manual procedures. The CompuMed computer aided diagnostic (CAD) application is readily accessible, since it utilizes widely available x-ray technology.
McLaughlin added, "The advent of costly biotech drugs for treating arthritis presents healthcare providers with a mandate for monitoring this disease, which affects more than 40 million Americans. Our arthritis application will be an aid to pharmaceutical companies and clinicians alike."
The arthritis application is a spin-off of CompuMed's OsteoGram CAD system to screen and diagnose osteoporosis -- a global disease that affects more than 200 million people worldwide. The newer DICOM OsteoGram was developed to take advantage of the growing market for digital x-ray and mammography equipment, as well as networking systems. CompuMed licenses the DICOM OsteoGram software to manufacturers of digital imaging equipment for placement at the point-of-sale.
About CompuMed:
Founded in 1973, CompuMed, Inc. (CMPD.OB) is leading the development of advanced imaging and medical informatics solutions that provide cost effective analysis and monitoring. CompuMed focuses on cardiovascular and musculoskeletal diseases, as well as other diseases associated with aging populations. Its unique expertise in telemonitoring, imaging and analysis facilitates the development of new solutions and services designed to improve healthcare provider workflow and patient care, while reducing costs. CompuMed's core products, the OsteoGramŽ and CardioGramTM systems, are cleared by the FDA and reimbursable by Medicare. The OsteoGram is an accurate and precise technology for osteoporosis testing. The underlying OsteoGram technology has significant cost advantages over other technologies and will be applied to a suite of value-added applications, such as following the progression of arthritic disease and diagnosing vertebral fractures and scoliosis. The CardioGram system is one of the first telecommunication networks designed to remotely interpret electrocardiograms, and is used by private practice, as well as government and corporate healthcare providers nationwide. The CardioGram delivers online electrocardiogram interpretations within two minutes of receipt, and has the additional capability to automatically provide an over-read (i.e., follow-up review) by a cardiologist. CompuMed is headquartered in Los Angeles. Visit CompuMed at www.compumed.net.
About ESCEO:
The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical companies developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of Osteoporosis and Osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception.
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning CompuMed's plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are not statements of historical fact. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company's filings with the Securities and Exchange Commission. All such forward-looking statements are expressly qualified by these cautionary statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
CONTACT: Susan Tellem - Tellem Worldwide, +1 (310) 479-6111 x.16.